BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 31160638)

  • 61. More is better: combination therapies for myelodysplastic syndromes.
    Ornstein MC; Mukherjee S; Sekeres MA
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):22-31. PubMed ID: 25659727
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Epigenetic Combination Therapy for Children With Secondary Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) and Concurrent Solid Tumor Relapse.
    Glasser CL; Lee A; Eslin D; Marks L; Modak S; Glade Bender JL
    J Pediatr Hematol Oncol; 2017 Oct; 39(7):560-564. PubMed ID: 28562519
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Synergistic effects of PRIMA-1
    Maslah N; Salomao N; Drevon L; Verger E; Partouche N; Ly P; Aubin P; Naoui N; Schlageter MH; Bally C; Miekoutima E; Rahmé R; Lehmann-Che J; Ades L; Fenaux P; Cassinat B; Giraudier S
    Haematologica; 2020 Jun; 105(6):1539-1551. PubMed ID: 31488557
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis.
    Lepelley P; Preudhomme C; Vanrumbeke M; Quesnel B; Cosson A; Fenaux P
    Leukemia; 1994 Aug; 8(8):1342-9. PubMed ID: 8057671
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Daver N; Kantarjian H; Ravandi F; Estey E; Wang X; Garcia-Manero G; Jabbour E; Konopleva M; O'Brien S; Verstovsek S; Kadia T; Dinardo C; Pierce S; Huang X; Pemmaraju N; Diaz-Pines-Mateo M; Cortes J; Borthakur G
    Leukemia; 2016 Feb; 30(2):268-73. PubMed ID: 26365212
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).
    Lübbert M; Ihorst G; Sander PN; Bogatyreva L; Becker H; Wijermans PW; Suciu S; Bissé E; Claus R
    Br J Haematol; 2017 Feb; 176(4):609-617. PubMed ID: 27905102
    [TBL] [Abstract][Full Text] [Related]  

  • 67. High-level MYC expression associates with poor survival in patients with acute myeloid leukemia and collaborates with overexpressed p53 in leukemic transformation in patients with myelodysplastic syndrome.
    Gao L; Saeed A; Golem S; Zhang D; Woodroof J; McGuirk J; Ganguly S; Abhyankar S; Lin TL; Cui W
    Int J Lab Hematol; 2021 Feb; 43(1):99-109. PubMed ID: 32812335
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The Problem of TP53-Mutant MDS/AML.
    Sallman DA
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S65-S66. PubMed ID: 32862873
    [No Abstract]   [Full Text] [Related]  

  • 69.
    Santini V; Stahl M; Sallman DA
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432650. PubMed ID: 38768424
    [No Abstract]   [Full Text] [Related]  

  • 70. Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects.
    Ureshino H; Kurahashi Y; Watanabe T; Yamashita S; Kamachi K; Yamamoto Y; Fukuda-Kurahashi Y; Yoshida-Sakai N; Hattori N; Hayashi Y; Kawaguchi A; Tohyama K; Okada S; Harada H; Ushijima T; Kimura S
    Mol Cancer Ther; 2021 Aug; 20(8):1412-1421. PubMed ID: 34045225
    [TBL] [Abstract][Full Text] [Related]  

  • 71. DICER1 gene and miRNA dysregulation in mesenchymal stem cells of patients with myelodysplastic syndrome and acute myeloblastic leukemia.
    Ozdogan H; Gur Dedeoglu B; Oztemur Islakoglu Y; Aydos A; Kose S; Atalay A; Yegin ZA; Avcu F; Uckan Cetinkaya D; Ilhan O
    Leuk Res; 2017 Dec; 63():62-71. PubMed ID: 29102598
    [TBL] [Abstract][Full Text] [Related]  

  • 72. ASXL1 and SETBP1 mutations promote leukaemogenesis by repressing TGFβ pathway genes through histone deacetylation.
    Saika M; Inoue D; Nagase R; Sato N; Tsuchiya A; Yabushita T; Kitamura T; Goyama S
    Sci Rep; 2018 Oct; 8(1):15873. PubMed ID: 30367089
    [TBL] [Abstract][Full Text] [Related]  

  • 73. CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine.
    Allan JN; Roboz GJ; Askin G; Ritchie E; Scandura J; Christos P; Hassane DC; Guzman ML
    Leuk Lymphoma; 2018 Apr; 59(4):821-828. PubMed ID: 28718760
    [TBL] [Abstract][Full Text] [Related]  

  • 74. PUMA promotes apoptosis of hematopoietic progenitors driving leukemic progression in a mouse model of myelodysplasia.
    Guirguis AA; Slape CI; Failla LM; Saw J; Tremblay CS; Powell DR; Rossello F; Wei A; Strasser A; Curtis DJ
    Cell Death Differ; 2016 Jun; 23(6):1049-59. PubMed ID: 26742432
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The emerging role of immune checkpoint based approaches in AML and MDS.
    Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N
    Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cyclosporine enhances the sensitivity to lenalidomide in MDS/AML in vitro.
    He X; Dou A; Feng S; Roman-Rivera A; Hawkins C; Lawley L; Zhang J; Wunderlich M; Mizukawa B; Halene S; Patel A; Fang J
    Exp Hematol; 2020 Jun; 86():21-27.e2. PubMed ID: 32437909
    [TBL] [Abstract][Full Text] [Related]  

  • 77. AML/MDS with 11q/MLL amplification show characteristic gene expression signature and interplay of DNA copy number changes.
    Zatkova A; Merk S; Wendehack M; Bilban M; Muzik EM; Muradyan A; Haferlach C; Haferlach T; Wimmer K; Fonatsch C; Ullmann R
    Genes Chromosomes Cancer; 2009 Jun; 48(6):510-20. PubMed ID: 19306356
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.
    Cashen AF; Schiller GJ; O'Donnell MR; DiPersio JF
    J Clin Oncol; 2010 Feb; 28(4):556-61. PubMed ID: 20026803
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
    Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
    Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.
    Gaballa MR; Besa EC
    Ann Hematol; 2014 May; 93(5):723-33. PubMed ID: 24627193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.